Frontiers of Science: Prof. Dipanjan Chowdhury
April 13th at 12:00
Presidentti auditorium, BioCity
Spring 2023 program
Prof. Dipanjan Chowdhury, Dana-Farber Cancer Institute, Harvard Medivcal School, USA
Expanding the scope of DNA repair factors- novel roles and applications
host: Jukka Westermarck (email@example.com)
Coffee and sandwich served at 11:45
Six students and early-career postdocs are welcome to have a lunch in restaurant Mauno and discuss with Prof. Chowdhury after the seminar. This is a great possibility to learn hosting skills in friendly environment and create connections for future. Every student are welcome to join, in spite of which research group they belong to. BioCity Turku will offer the lunch.
If you got interested, please send an email to firstname.lastname@example.org
The Dipanjan Chowdhury Lab investigates how human cells sense and repair DNA damage. Loss of genome integrity due to DNA damage has long been established as a critical contributor to cancer and tumorigenesis. Our work therefore focuses on how cells maintain genome integrity. Through genetic, biochemical, and proteomic approaches, as well as collaboration with structural biologists, computational biologists and mouse geneticists, we aim to achieve better understanding in cancer etiology and the development of effective cancer diagnoses and therapies.Whether it is searching for potential treatments to radiation exposure, or the causes and treatment of ovarian cancer, we strive for research that makes a positive impact.
Iyer DR, Harada N, Clairmont C, Jiang L, Martignetti D, Nguyen H, He YJ, Chowdhury D, D’Andrea AD. 2022. CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining. Proc Natl Acad Sci U S A. 119:e2214935119
da Costa AABA, Chowdhury D, Shapiro GI, D’Andrea AD, Konstantinopoulos PA. 2022. Targeting replication stress in cancer therapy. Nat Rev Drug Discov. in press
Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, Nguyen QD, Jones KL, Moreau LA, Peng J, Dipiazza MG, Perciaccante AJ, Zhu X, Hunsel BR, Liu KX, Alexandrescu S, Drissi R, Filbin MG, McBrayer SK, Agar NYR, Chowdhury D, Haas-Kogan DA. 2022. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell. 40:957-972.e10
Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, Maliga Z, Yapp C, Chen YA, Schapiro D, Zhou Y, Graham JR, Dezube BJ, Munster P, Santagata S, Garcia E, Rodig S, Lako A, Chowdhury D, Shapiro GI, Matulonis UA, Park PJ, Hautaniemi S, Sorger PK, Swisher EM, D’Andrea AD, Konstantinopoulos PA. 2020. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 11:1459
Sarek G, Kotsantis P, Ruis P, Van Ly D, Margalef P, Borel V, Zheng XF, Flynn HR, Snijders AP, Chowdhury D, Cesare AJ, Boulton SJ. 2019. CDK phosphorylation of TRF2 controls t-loop dynamics during the cell cycle. Nature. 575:523-527
- You can download all spring 2023 FoS-seminars in your calendar from here: https://seafile.utu.fi/d/4a0b831f23ef420786b0/
- Registration is not needed for the on-site seminars
- Participation list is circulated in the audience
- If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, please print out this seminar diary and after the seminar ask the BioCity coordinator to sign it
- Please note that any audio or video recording of the seminars is strictly forbidden.